Etomidate Use for Rapid Sequence Intubation Is Not Associated With Nosocomial Infection.

Autor:	Hidalgo DC; Department of Medicine, Loyola University Medical Center, Maywood, IL, USA., Amin V; Department of Pharmacy, Loyola University Medical Center, Maywood, IL, USA., Hukku A; Department of Medicine, Loyola University Medical Center, Maywood, IL, USA., Kutlu K; Department of Anesthesiology, Loyola University Medical Center, Maywood, IL, USA., Rech MA; Department of Pharmacy, Loyola University Medical Center, Maywood, IL, USA.; Department of Emergency Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.
Jazyk:	angličtina
Zdroj:	Journal of pharmacy practice [J Pharm Pract] 2022 Jun; Vol. 35 (3), pp. 383-387. Date of Electronic Publication: 2020 Dec 11.
DOI:	10.1177/0897190020979610
Abstrakt:	Introduction: Etomidate is commonly used for induction of anesthesia for rapid sequence intubation (RSI). It has little impact on hemodynamic status, making it a widely used agent. Due to the inhibition of cortisol production, etomidate causes adrenal suppression. The purpose of this study is to determine whether there is a correlation with etomidate use and the incidence of secondary infections. Methods: This was a retrospective cohort of hospitalized patients who received either etomidate or control (ketamine, propofol, or no agent) for RSI. The primary endpoint was the incidence of secondary infections. Secondary outcomes included number of mechanical ventilator-free days within 28 days, 30-day mortality, length of hospital stay, and length of intensive care unit stay. Results: A total of 434 patients were reviewed, of which 129 (29.7%) met the study criteria (n = 94 etomidate; n = 35 control). The incidence of secondary infection was numerically higher in the etomidate group compared with the control group, though this was not statistically significant (38.7% vs. 28.6%, p = 0.447). Also, though the secondary outcomes showed no statistically significant difference between the groups, the patients in the control group had a longer hospital stay (14.0 vs. 18.1, p = 0.20) and a longer ICU stay (11.0 vs. 14.1, p = 030). Furthermore, the etomidate group had a non-statistically significant higher incidence of bacteremia (8 vs. 0, p = 0.17). Conclusion: The use of etomidate was not associated with increased incidence of secondary infection. To fully understand the effects of etomidate use and its subsequent adrenal suppression, larger studies are needed.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu